Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – December 2016

ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer Dec 6, 2016 Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the … Continue reading Top Pharma News – December 2016

Advertisements
Eli Lilly Logo

Lilly’s Baricitinib is Recommended by CHMP for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

Dec. 16, 2016 Eli Lilly and Company and Incyte Corporation have announced that the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) has issued a positive opinion recommending the approval of baricitinib - which if approved, would be marketed as Olumiant®. Baricitinib is recommended to be used for treating moderate to severe active rheumatoid arthritis … Continue reading Lilly’s Baricitinib is Recommended by CHMP for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Fall 2016

AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen July 25, 2016 AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen … Continue reading Pharma Oncology | Top News – Fall 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – September and October, 2016

  Bristol-Myers Squibb’s ORENCIA® (abatacept) is Approved by European Commission for the Treatment of Adult Patients with Rheumatoid Arthritis September 6, 2016 Bristol-Myers Squibb Company has announced that the European Commission has approved ORENCIA ® (abatacept) intravenous (IV) infusion and subcutaneous (SC) injection, combined with methotrexate (MTX), for treating highly active and progressive disease in adult patients with rheumatoid … Continue reading Top Pharma News – September and October, 2016

Pfizer logo

Pfizer Gets Positive CHMP Opinion for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for The Treatment of HR+/HER2- Metastatic Breast Cancer in Europe

September 16, 2016 Pfizer Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE® (palbociclib) be granted marketing authorization in the European Union (EU) for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced … Continue reading Pfizer Gets Positive CHMP Opinion for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for The Treatment of HR+/HER2- Metastatic Breast Cancer in Europe

Eisai

Eisai Receives Positive CHMP Opinion on the Anticancer Agent Lenvatinib in Combination with Everolimus for Treating Advanced Renal Cell Carcinoma

July 22, 2016 Eisai Co., Ltd. has announced that its European regional headquarter has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency on anticancer agent lenvatinib mesylate (generic name,“lenvatinib”) in combination with everolimus for treating adult patients with advanced renal cell carcinoma (RCC) following one … Continue reading Eisai Receives Positive CHMP Opinion on the Anticancer Agent Lenvatinib in Combination with Everolimus for Treating Advanced Renal Cell Carcinoma

Roche logo

EMA and FDA accept Marketing applications of Roche for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis

28 June 2016 Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of OCREVUS® (ocrelizumab) in the European Union (EU) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This Validation confirms that the submission is complete and signifies the MAA is under review … Continue reading EMA and FDA accept Marketing applications of Roche for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis

Merck Igea Luca Dezzani

KEYTRUDA® (pembrolizumab) of Merck Receives Positive CHMP Opinion for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

June 27, 2016 Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) … Continue reading KEYTRUDA® (pembrolizumab) of Merck Receives Positive CHMP Opinion for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma Oncology | Top News – Spring 2016

GSK Returns to War against Cancer April 3, 2016 It looked like the UK pharmaceuticals group GlaxoSmithKline (GSK) was declaring surrender in the war on cancer when the company agreed to sell its oncology drugs for $16 billion to Novartis in 2014. However, after two years, GSK returns to this war on cancer again.   … Continue reading Pharma Oncology | Top News – Spring 2016

abbvie logo

HUMIRA® (adalimumab) of AbbVie Receives CHMP Positive Opinion for the Treatment of Certain Forms of Non-Infectious Uveitis

May 27, 2016 AbbVie, a global biopharmaceutical company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of non-infectious uveitis in adult patients who have had an inadequate response to corticosteroids or in whom corticosteroid treatment … Continue reading HUMIRA® (adalimumab) of AbbVie Receives CHMP Positive Opinion for the Treatment of Certain Forms of Non-Infectious Uveitis